NCCN has the following processes in place to ensure transparency of the NCCN Guidelines update process.
Acute Lymphoblastic Leukemia Panel
Version: 2.2023
Date: 2023-06-21 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023
Date: 2023-04-27 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023
Date: 2022-11-02 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-11-19 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2021
Date: 2021-11-19 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2021
Date: 2021-07-13 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2021-02-10 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-11-06 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-10-03 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2019
Date: 2019-02-22 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2019
Date: 2018-11-27 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023
Date: 2022-04-08 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2022 ( Acute Myeloid Leukemia )
Date: 2022-04-08 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2022 ( Acute Myeloid Leukemia )
Date: 2021-11-02 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Acute Myeloid Leukemia )
Date: 2021-11-02 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Acute Myeloid Leukemia )
Date: 2021-10-18 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Acute Myeloid Leukemia )
Date: 2021-05-13 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-09-30 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-05-26 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-05-19 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2020
Date: 2020-09-16 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2020
Date: 2019-12-18 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2020
Date: 2019-08-20 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( Acute Myeloid Leukemia )
Date: 2019-05-14 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2018
Date: 2018-11-28 Meeting Evidence Panel Disclosures/Attendance
Adolescent and Young Adult Oncology Panel
Version: 3.2023
Date: 2022-12-20 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Adult Cancer Pain )
Date: 2022-09-12 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-09-03 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-12-05 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-10-01 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Antiemesis )
Date: 2021-09-24 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-09-17 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-09-12 Meeting Evidence Panel Disclosures/Attendance
Version: 5.2023
Date: 2023-06-29 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2023 ( B-Cell Lymphomas )
Date: 2023-05-25 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2023 ( B-Cell Lymphomas )
Date: 2023-04-26 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2023 ( B-Cell Lymphomas )
Date: 2023-02-01 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( B-Cell Lymphomas )
Date: 2022-09-21 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( B-Cell Lymphomas )
Date: 2022-09-20 Meeting Evidence Panel Disclosures/Attendance
Version: 5.2022
Date: 2022-06-30 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2022 ( B-Cell Lymphomas )
Date: 2022-06-01 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( B-Cell Lymphomas )
Date: 2022-01-21 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( B-Cell lymphomas )
Date: 2021-12-06 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( B-Cell Lymphomas )
Date: 2021-09-28 Meeting Evidence Panel Disclosures/Attendance
Version: 5.2021 ( B-Cell Lymphomas )
Date: 2021-09-15 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2021
Date: 2021-04-28 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2021
Date: 2021-03-10 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2021
Date: 2021-02-09 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-12-22 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-09-22 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2020
Date: 2020-08-04 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2020
Date: 2020-07-28 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2020
Date: 2020-06-23 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-12-18 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-11-11 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-09-23 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-09-04 Meeting Evidence Panel Disclosures/Attendance
Version: 7.2019
Date: 2019-12-05 Meeting Evidence Panel Disclosures/Attendance
Version: 6.2019
Date: 2019-11-18 Meeting Evidence Panel Disclosures/Attendance
Version: 5.2019
Date: 2019-09-04 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2019
Date: 2019-06-11 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2019
Date: 2019-02-12 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2019
Date: 2018-11-05 Meeting Evidence Panel Disclosures/Attendance
Version: 5.2018
Date: 2018-09-26 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2023 ( Bladder )
Date: 2022-08-26 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2023 ( Bladder Cancer )
Date: 2022-08-26 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Bladder Cancer )
Date: 2022-08-26 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2022 ( Bladder Cancer )
Date: 2022-12-21 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Bladder Cancer )
Date: 2021-09-24 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Penile Cancer )
Date: 2021-09-24 Meeting Evidence Panel Disclosures/Attendance
Version: 5.2021 ( Bladder Cancer )
Date: 2021-10-12 Meeting Evidence Panel Disclosures/Attendance
Date: 2021-10-12 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2021 ( Bladder Cancer )
Date: 2021-07-13 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2021 ( Bladder Cancer )
Date: 2021-06-28 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2021 ( Bladder Cancer )
Date: 2021-04-14 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2021 ( Bladder Cancer )
Date: 2021-03-11 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021 ( Bladder Cancer )
Date: 2021-02-22 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021 ( Bladder Cancer )
Date: 2020-09-29 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021 ( Penile Cancer )
Date: 2020-09-29 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021 ( Bladder Cancer )
Date: 2020-09-18 Meeting Evidence Panel Disclosures/Attendance
Version: 6.2020 ( Bladder Cancer )
Date: 2020-07-02 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2020 ( Bladder Cancer )
Date: 2020-04-21 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2020 ( Bladder Cancer )
Date: 2020-01-14 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2020 ( Bladder Cancer )
Date: 2019-12-19 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( Bladder Cancer )
Date: 2019-11-04 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( Bladder Cancer )
Date: 2019-09-20 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( Penile Cancer )
Date: 2019-09-20 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2019 ( Bladder Cancer )
Date: 2019-04-16 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2019 ( Bladder Cancer )
Date: 2019-03-27 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2019 ( Bladder Cancer )
Date: 2019-03-06 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2019 ( Bladder Cancer )
Date: 2019-03-01 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2019 ( Bladder Cancer )
Date: 2018-09-24 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2024 ( Bone Cancer )
Date: 2023-05-22 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2023 ( Bone Cancer )
Date: 2022-08-23 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Bone Cancer )
Date: 2022-05-02 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-05-21 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-08-12 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-06-12 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-05-08 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-09-05 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-05-03 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2023 ( Breast Cancer )
Date: 2023-03-08 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2023 ( Breast Cancer )
Date: 2023-01-31 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Breast Cancer )
Date: 2022-10-28 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Breast Cancer )
Date: 2022-08-26 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Breast Cancer )
Date: 2022-08-25 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2022 ( Breast Cancecr )
Date: 2022-06-16 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2022
Date: 2021-12-17 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-10-18 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-08-12 Meeting Evidence Panel Disclosures/Attendance
Version: 8.2021
Date: 2021-08-30 Meeting Evidence Panel Disclosures/Attendance
Version: 6.2021
Date: 2021-08-12 Meeting Evidence Panel Disclosures/Attendance
Version: 5.2021
Date: 2021-06-14 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2021
Date: 2021-04-23 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2021
Date: 2021-02-23 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-12-01 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-08-27 Meeting Evidence Panel Disclosures/Attendance
Version: 6.2020
Date: 2020-08-27 Meeting Evidence Panel Disclosures/Attendance
Version: 5.2020
Date: 2020-07-07 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2020
Date: 2020-05-04 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2020
Date: 2020-04-27 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2020
Date: 2020-04-21 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2020
Date: 2020-02-27 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2020
Date: 2020-01-30 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-08-16 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-08-15 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2019
Date: 2019-08-16 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2019
Date: 2019-06-13 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2019
Date: 2019-03-11 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2018
Date: 2019-01-23 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2018
Date: 2018-10-19 Meeting Evidence Panel Disclosures/Attendance
Breast Cancer Risk Reduction Panel
Version: 1.2023 ( Breast Cancer Risk Reduction )
Date: 2022-09-06 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Breast Cancer Risk Reduction )
Date: 2022-07-26 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-08-14 Meeting Evidence Panel Disclosures/Attendance
Breast Cancer Screening and Diagnosis Panel
Version: 1.2023 ( Breast Cancer Screening and Diagnosis )
Date: 2022-11-18 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2019 ( Breast Cancer Screening and Diagnosis )
Date: 2018-11-13 Meeting Evidence Panel Disclosures/Attendance
Cancer in People with HIV/Kaposi Sarcoma Panel
Version: 1.2023 ( Kaposi Sarcoma )
Date: 2022-08-02 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Cancer in People with HIV )
Date: 2021-09-14 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Kaposi Sarcoma )
Date: 2021-09-14 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021 ( Kaposi Sarcoma )
Date: 2020-08-31 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2020 ( AIDS-Related Kaposi Sarcoma )
Date: 2020-05-21 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( AIDS-Related Kaposi Sarcoma )
Date: 2019-08-12 Meeting Evidence Panel Disclosures/Attendance
Cancer-Associated Venous Thromboembolic Disease Panel
Version: 1.2021
Date: 2020-11-20 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2020-04-01 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2020-03-17 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2019
Date: 2019-02-01 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2019
Date: 2019-01-18 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2019
Date: 2018-12-12 Meeting Evidence Panel Disclosures/Attendance
Central Nervous System Cancers Panel
Version: 1.2023 ( Central Nervous System Cancers )
Date: 2023-02-16 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Central Nervous System Cancers )
Date: 2022-10-27 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Central Nervous System Cancers )
Date: 2022-04-19 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Central Nervous System Cancers )
Date: 2021-11-17 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Central Nervous System Cancers )
Date: 2021-10-21 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2021
Date: 2021-08-27 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2021-04-29 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-10-23 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2020
Date: 2021-03-04 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2020
Date: 2020-04-22 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2020-02-05 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-10-04 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2019
Date: 2019-09-09 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2019
Date: 2019-09-09 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2019
Date: 2019-01-26 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2019
Date: 2018-10-03 Meeting Evidence Panel Disclosures/Attendance
Cervical/Uterine Cancers Panel
Version: 2.2023 ( Uterine Neoplasms )
Date: 2023-04-07 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2023 ( Uterine Neoplasms )
Date: 2023-03-21 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Cervical Cancer )
Date: 2022-11-14 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Uterine Neoplasms )
Date: 2022-11-14 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Vulvar Cancer )
Date: 2022-11-14 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Cervical Cancer )
Date: 2022-06-28 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Uterine Neoplasms )
Date: 2022-06-28 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Vulvar Cancer )
Date: 2022-06-28 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Cervical Cancer )
Date: 2021-10-08 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Uterine Neoplasms )
Date: 2021-10-08 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Uterine Neoplasms )
Date: 2021-08-14 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Cervical Cancer )
Date: 2021-06-11 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Gestational Trophoblastic Neoplasia )
Date: 2021-06-11 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Uterine Neoplasms )
Date: 2021-06-11 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Vulvar Cancer )
Date: 2021-06-11 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2021 ( Uterine Neoplasms )
Date: 2021-08-14 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2021 ( Uterine Neoplasms )
Date: 2021-06-11 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2021 ( Uterine Neoplasms )
Date: 2021-04-27 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021 ( Uterine Neoplasms )
Date: 2020-09-02 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021 ( Vulvar Cancer )
Date: 2020-09-02 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021 ( Cervical Cancer )
Date: 2020-06-12 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021 ( Uterine Neoplasms )
Date: 2020-06-12 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021 ( Vulvar Cancer )
Date: 2020-06-12 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2020 ( Gestational Trophoblastic Neoplasia )
Date: 2020-09-02 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2020 ( Vulvar Cancer )
Date: 2020-07-07 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2020 ( Cervical Cancer )
Date: 2020-07-07 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2020 ( Uterine Neoplasms )
Date: 2020-07-07 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2020 ( Gestational Trophoblastic Neoplasia )
Date: 2020-05-01 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( Cervical Cancer )
Date: 2019-11-26 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( Cervical Cancer )
Date: 2019-09-13 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( Uterine Neoplasms )
Date: 2019-09-13 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( Cervical Cancer )
Date: 2019-06-11 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( Uterine Neoplasms )
Date: 2019-06-11 Meeting Evidence Panel Disclosures/Attendance
Version: 5.2019 ( Uterine Neoplasms )
Date: 2019-11-25 Meeting Evidence Panel Disclosures/Attendance
Version: 5.2019 ( Cervical Cancer )
Date: 2019-08-26 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2019 ( Uterine Neoplasms )
Date: 2019-08-26 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2019 ( Uterine Neoplasms )
Date: 2019-02-01 Meeting Evidence Panel Disclosures/Attendance
Chronic Myeloid Leukemia Panel
Version: 1.2024
Date: 2023-05-23 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023
Date: 2022-05-17 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2022 ( Chronic Myeloid Leukemia )
Date: 2021-11-03 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2021
Date: 2021-01-05 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-05-31 Meeting Evidence Panel Disclosures/Attendance
CLL/SLL/Hairy Cell Leukemia Panel
Version: 3.2023 ( CLL/SLL )
Date: 2023-06-01 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2023 ( Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma )
Date: 2022-12-22 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma )
Date: 2022-08-08 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma )
Date: 2022-07-11 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Hairy Cell Leukemia )
Date: 2022-07-11 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma )
Date: 2022-06-17 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2022 ( Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma )
Date: 2022-01-25 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2022 ( Chronic LymphoChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma cytic Leukemia/ Small Lymphocy )
Date: 2022-01-14 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma )
Date: 2021-07-14 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma )
Date: 2021-06-04 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Hairy Cell Leukemia )
Date: 2021-06-04 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2021 ( Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma )
Date: 2020-11-02 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021 ( Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma )
Date: 2020-06-30 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021 ( Hairy Cell Leukemia )
Date: 2020-06-30 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021 ( Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma )
Date: 2020-06-05 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021 ( Hairy Cell Leukemia )
Date: 2020-06-05 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2020 ( Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma )
Date: 2020-01-17 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2020 ( Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma )
Date: 2019-11-25 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2020 ( Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma )
Date: 2019-10-01 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma )
Date: 2019-08-06 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma )
Date: 2019-07-11 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma )
Date: 2019-06-17 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma )
Date: 2019-06-07 Meeting Evidence Panel Disclosures/Attendance
Version: 5.2019 ( Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma )
Date: 2019-05-16 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2019 ( Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma )
Date: 2019-02-11 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2019 ( Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma )
Date: 2019-01-31 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2019 ( Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma )
Date: 2018-10-01 Meeting Evidence Panel Disclosures/Attendance
Colon/Rectal/Anal Cancers Panel
Version: 4.2023 ( Rectal Cancer )
Date: 2023-06-29 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2023 ( Rectal Cancer )
Date: 2023-04-14 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Colon/Rectal Cancers )
Date: 2023-03-06 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Anal Carcinoma )
Date: 2022-08-31 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Colon/Rectal Cancers )
Date: 2022-08-31 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Small Bowel Adenocarcinoma )
Date: 2022-08-31 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Anal Carcinoma )
Date: 2022-08-30 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Colon/Rectal Cancers )
Date: 2022-08-30 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2022 ( Rectal Cancer )
Date: 2022-08-31 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2022 ( Rectal Cancer )
Date: 2022-10-17 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2022 ( Colon Cancer )
Date: 2022-08-31 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2022 ( Colon Cancer )
Date: 2022-10-17 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2022 ( Small Bowel Adenocarcinoma )
Date: 2022-10-17 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Anal Carcinoma )
Date: 2021-09-09 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Small Bowel Adenocarcinoma )
Date: 2021-09-09 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Colon/Rectal Cancers )
Date: 2021-08-02 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2021 ( Colon Cancer )
Date: 2021-08-24 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2021 ( Rectal Cancer )
Date: 2021-08-24 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2021 ( Small Bowel Adenocarcinoma )
Date: 2021-08-24 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021 ( Anal Carcinoma )
Date: 2021-02-02 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021 ( Small Bowel Adenocarcinoma )
Date: 2021-02-02 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021 ( Anal Carcinoma )
Date: 2020-09-29 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021 ( Colon/Rectal Cancers )
Date: 2020-09-29 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021 ( Small Bowel Adenocarcinoma )
Date: 2020-09-29 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021 ( Colon/Rectal Cancers )
Date: 2020-08-11 Meeting Evidence Panel Disclosures/Attendance
Version: 5.2020 ( Rectal Cancer )
Date: 2020-06-04 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2020 ( Colon Cancer )
Date: 2020-06-04 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2020 ( Colon/Rectal Cancers )
Date: 2020-05-01 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2020 ( Anal Carcinoma )
Date: 2020-05-01 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2020 ( Small Bowel Adenocarcinoma )
Date: 2020-05-01 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2020 ( Colon/Rectal Cancers )
Date: 2020-02-04 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( Colon/Rectal Cancers )
Date: 2019-12-10 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( Anal Carcinoma )
Date: 2019-08-20 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( Colon/Rectal Cancers )
Date: 2019-08-20 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( Colon/Rectal Cancers )
Date: 2019-08-19 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2019 ( Colon/Rectal Cancers )
Date: 2019-08-20 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2019 ( Colon/Rectal Cancers )
Date: 2019-08-19 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2019 ( Colon/Rectal Cancers )
Date: 2019-04-25 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2019 ( Anal Carcinoma )
Date: 2019-02-27 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2019 ( Colon/Rectal Cancers )
Date: 2019-02-27 Meeting Evidence Panel Disclosures/Attendance
Colorectal Cancer Screening Panel
Version: 1.2022
Date: 2021-11-03 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-11-05 Meeting Evidence Panel Disclosures/Attendance
Esophageal/Gastric Cancers Panel
Version: 3.2023 ( Esophageal )
Date: 2023-08-07 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2023 ( Gastric )
Date: 2023-08-07 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Esophageal )
Date: 2023-01-27 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Gastric )
Date: 2023-01-27 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Esophageal )
Date: 2022-08-30 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Gastric )
Date: 2022-08-30 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2022 ( Esophageal )
Date: 2022-08-17 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2022 ( Esophageal )
Date: 2022-06-13 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2022 ( Gastric )
Date: 2022-06-13 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Esophageal )
Date: 2021-12-01 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Esophageal )
Date: 2021-09-08 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Gastric )
Date: 2021-09-08 Meeting Evidence Panel Disclosures/Attendance
Version: 5.2021 ( Gastric Cancer )
Date: 2021-09-08 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2021 ( Esophageal and Esophagogastric Cancer )
Date: 2021-07-13 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2021 ( Gastric Cancer )
Date: 2021-07-13 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2021 ( Esophageal and Esophagogastric Cancer )
Date: 2021-06-24 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2021 ( Esophageal Cancer )
Date: 2021-04-28 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2021 ( Gastric Cancer )
Date: 2021-04-28 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2021 ( Esophageal Cancer )
Date: 2021-02-11 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2021 ( Gastric Cancer )
Date: 2021-02-11 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021 ( Esophageal Cancer )
Date: 2020-12-24 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021 ( Gastric Cancer )
Date: 2020-12-24 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021 ( Esophageal Cancer )
Date: 2020-09-16 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021 ( Gastric Cancer )
Date: 2020-09-16 Meeting Evidence Panel Disclosures/Attendance
Version: 5.2020 ( Esophageal Cancer )
Date: 2020-12-11 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2020 ( Gastric Cancer )
Date: 2020-12-11 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2020 ( Esophageal Cancer )
Date: 2020-06-16 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2020 ( Esophageal and Esophagogastric Junction Cancers )
Date: 2020-05-01 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2020 ( Gastric Cancer )
Date: 2020-05-01 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( Esophageal Cancer )
Date: 2020-01-22 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( Gastric Cancer )
Date: 2020-01-22 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( Esophageal Cancer )
Date: 2019-10-22 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( Gastric Cancer )
Date: 2019-10-22 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( Esophageal Cancer )
Date: 2019-10-01 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( Gastric Cancer )
Date: 2019-10-01 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( Gastric Cancer )
Date: 2019-09-13 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2019 ( Esophageal Cancer )
Date: 2019-10-22 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2019 ( Gastric Cancer )
Date: 2019-10-22 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2019 ( Esophageal Cancer )
Date: 2019-09-13 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2019 ( Gastric Cancer )
Date: 2019-09-13 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2019 ( Esophageal Cancer )
Date: 2019-10-22 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2019 ( Gastric Cancer )
Date: 2019-10-22 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2019 ( Esophageal Cancer )
Date: 2019-10-01 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2019 ( Esophageal Cancer )
Date: 2019-09-13 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2019 ( Gastric Cancer )
Date: 2019-09-13 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2019 ( Esophageal Cancer )
Date: 2019-04-16 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2019 ( Gastric Cancer )
Date: 2019-04-16 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2019 ( Esophageal Cancer )
Date: 2019-01-10 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2019 ( Gastric Cancer )
Date: 2019-01-10 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2019 ( Esophageal Cancer )
Date: 2018-10-09 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2019 ( Gastric Cancer )
Date: 2018-10-09 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2019 ( Esophageal Cancer )
Date: 2018-09-25 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2019 ( Gastric Cancer )
Date: 2018-09-25 Meeting Evidence Panel Disclosures/Attendance
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Panel
Version: 1.2024
Date: 2023-04-11 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic )
Date: 2022-04-29 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-04-09 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-05-22 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-04-28 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-04-21 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-07-02 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-04-25 Meeting Evidence Panel Disclosures/Attendance
Genetic/Familial High-Risk Assessment: Colorectal Panel
Version: 1.2023 ( Genetic/Familial High-Risk Assessment: Colorectal Panel )
Date: 2022-12-06 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Genetics/Familial High-Risk Assessment: Colorectal )
Date: 2021-12-13 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Genetics/Familial High-Risk Assessment: Colorectal )
Date: 2021-12-07 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2021-02-02 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-12-14 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( Genetics/Familial High-Risk Assessment: Colorectal )
Date: 2020-03-03 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( Genetics/Familial High-Risk Assessment: Colorectal )
Date: 2019-12-03 Meeting Evidence Panel Disclosures/Attendance
Genetic: Colorectal/Colorectal Cancer Screening Panel
Version: 1.2019 ( Colorectal Cancer Screening )
Date: 2018-12-11 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2023
Date: 2023-04-26 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2023
Date: 2023-02-28 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023
Date: 2022-10-03 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023
Date: 2022-06-30 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-10-15 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-06-21 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-10-13 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-09-03 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-06-25 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-12-20 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-08-28 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2019
Date: 2019-08-28 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2019
Date: 2019-06-18 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2019
Date: 2019-02-26 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2019
Date: 2019-01-17 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2019
Date: 2018-10-12 Meeting Evidence Panel Disclosures/Attendance
Hematopoietic Cell Transplantation Panel
Version: 1.2023 ( Hematopoietic Cell Transplantation )
Date: 2022-11-04 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2022 ( Hematopoietic Cell Transplantation )
Date: 2022-09-14 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-11-16 Meeting Evidence Panel Disclosures/Attendance
Version: 5.2021
Date: 2021-09-24 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2021
Date: 2021-08-25 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2021
Date: 2021-07-20 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-12-17 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-11-16 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-11-13 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( Hematopoietic Cell Transplantation )
Date: 2019-09-27 Meeting Evidence Panel Disclosures/Attendance
Hematopoietic Growth Factors Panel
Version: 2.2023 ( Hematopoietic Growth Factors )
Date: 2023-02-24 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023
Date: 2022-10-21 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023
Date: 2022-08-31 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-10-18 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2021
Date: 2021-04-26 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2021
Date: 2021-02-18 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-10-14 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( Hematopoietic Growth Factors )
Date: 2019-10-03 Meeting Evidence Panel Disclosures/Attendance
Date: 2019-10-03 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2019 ( Hematopoietic Growth Factors )
Date: 2019-02-21 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2019 ( Hematopoietic Growth Factors )
Date: 2019-02-05 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2019 ( Hematopoietic Growth Factors )
Date: 2018-10-25 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Biliary Tract Cancers )
Date: 2023-02-17 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Hepatocellular Carcinoma )
Date: 2023-02-17 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Biliary Tract Cancers )
Date: 2022-11-17 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Hepatocellular Carcinoma )
Date: 2022-11-17 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2022 ( Hepatobiliary Cancers )
Date: 2022-11-17 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2022 ( Hepatobiliary Cancers )
Date: 2022-10-05 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2022 ( Hepatobiliary Cancers )
Date: 2022-07-01 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Hepatobiliary Cancers )
Date: 2022-03-11 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Hepatobiliary Cancers )
Date: 2022-02-24 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Hepatobiliary Cancers )
Date: 2022-02-09 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Hepatobiliary Cancers )
Date: 2021-10-07 Meeting Evidence Panel Disclosures/Attendance
Version: 5.2021 ( Hepatobiliary Cancers )
Date: 2021-09-01 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2021
Date: 2021-08-13 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2021
Date: 2021-06-03 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2021-01-20 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-12-10 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-10-29 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2020
Date: 2020-06-09 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2020
Date: 2020-05-15 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2020
Date: 2020-04-20 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2020-03-16 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2020-01-31 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-11-19 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-10-15 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2019
Date: 2019-11-19 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2019
Date: 2019-03-01 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2019
Date: 2018-09-27 Meeting Evidence Panel Disclosures/Attendance
Version: 5.2018
Date: 2018-11-13 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2018
Date: 2018-09-27 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Histiocytic Neoplasms )
Date: 2022-12-02 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Histiocytic Neoplasms )
Date: 2021-12-16 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023
Date: 2022-07-29 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023
Date: 2022-04-27 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-08-30 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-08-19 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-11-30 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-08-18 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-07-26 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2024
Date: 2023-06-01 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2024
Date: 2023-04-21 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2023
Date: 2022-12-16 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2023 ( Kidney Cancer )
Date: 2022-09-13 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Kidney Cancer )
Date: 2022-05-10 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Kidney Cancer )
Date: 2022-04-08 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2022
Date: 2021-12-10 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2022
Date: 2021-08-19 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-05-14 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-04-30 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2021
Date: 2021-03-04 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2021
Date: 2021-03-04 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2021
Date: 2021-02-13 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2021
Date: 2021-01-25 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-04-03 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2020
Date: 2019-07-19 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-05-22 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-04-17 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-04-12 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2019
Date: 2019-04-12 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023
Date: 2022-07-12 Meeting Evidence Panel Disclosures/Attendance
Management of Immunotherapy-Related Toxicity Panel
Version: 2.2023
Date: 2023-04-20 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2023
Date: 2023-02-01 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023
Date: 2022-07-15 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Management of Immunotherapy-Related Toxicities )
Date: 2022-02-15 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Management of Immunotherapy-Related Toxicities )
Date: 2022-02-03 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Management of Immunotherapy-Related Toxicities )
Date: 2021-12-09 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Management of Immunotherapy-Related Toxicities )
Date: 2021-07-16 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2021 ( Management of Immunotherapy-Related Toxicities )
Date: 2021-09-23 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2021
Date: 2021-03-10 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-12-11 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-07-14 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-08-12 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-07-23 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2019
Date: 2018-10-05 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2023 ( Melanoma: Cutaneous )
Date: 2023-02-04 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Melanoma: Uveal )
Date: 2023-03-24 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Melanoma: Cutaneous )
Date: 2022-11-22 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Melanoma: Cutaneous )
Date: 2022-07-14 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2022 ( Melanoma: Cutaneous )
Date: 2022-03-23 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2022 ( Melanoma: Cutaneous )
Date: 2021-12-23 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Melanoma: Uveal )
Date: 2022-03-07 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Cutaneous Melanoma )
Date: 2021-10-10 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Cutaneous Melanoma )
Date: 2021-07-19 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Cutaneous Melanoma )
Date: 2021-07-12 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2021 ( Cutaneous Melanoma )
Date: 2021-01-29 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-10-12 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-07-13 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2020
Date: 2020-08-05 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2020 ( Uveal Melanoma )
Date: 2020-09-03 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-11-22 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-07-21 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2019
Date: 2019-09-03 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2019
Date: 2019-07-21 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2019
Date: 2019-02-01 Meeting Evidence Panel Disclosures/Attendance
Multiple Myeloma/Systemic Light Chain Amyloidosis/Waldenström Macroglobulinemia Panel
Version: 4.2023 ( Multiple Myeloma )
Date: 2023-08-15 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2023 ( Multiple Myeloma )
Date: 2023-08-10 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2023 ( Multiple Myeloma )
Date: 2022-11-23 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2023 ( Multiple Myeloma )
Date: 2022-10-26 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Multiple Myeloma )
Date: 2022-04-28 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Systemic Light Chain Amyloidosis )
Date: 2022-04-28 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Waldenström Macroglobulinemia Panel )
Date: 2022-04-28 Meeting Evidence Panel Disclosures/Attendance
Version: 5.2022 ( Multiple Myeloma )
Date: 2022-03-02 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2022 ( Multiple Myeloma )
Date: 2021-12-03 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2022 ( Multiple Myeloma )
Date: 2021-10-25 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2022 ( Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma )
Date: 2021-11-23 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2022 ( Multiple Myeloma )
Date: 2021-10-11 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Multiple Myeloma )
Date: 2021-04-16 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Systemic Light Chain Amyloidosis )
Date: 2021-04-16 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma )
Date: 2021-04-16 Meeting Evidence Panel Disclosures/Attendance
Version: 6.2021 ( Multiple Myeloma )
Date: 2021-03-29 Meeting Evidence Panel Disclosures/Attendance
Version: 5.2021 ( Multiple Myeloma )
Date: 2021-03-01 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2021 ( Multiple Myeloma )
Date: 2020-11-16 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2021 ( Systemic Light Chain Amyloidosis )
Date: 2021-01-28 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2021 ( Multiple Myeloma )
Date: 2020-09-01 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021 ( Multiple Myeloma )
Date: 2020-08-13 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021 ( Multiple Myeloma )
Date: 2020-07-22 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021 ( Multiple Myeloma )
Date: 2020-04-20 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021 ( Systemic Light Chain Amyloidosis )
Date: 2020-04-20 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021 ( Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma )
Date: 2020-04-20 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2020 ( Multiple Myeloma )
Date: 2020-05-04 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2020 ( Multiple Myeloma )
Date: 2020-03-03 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2020 ( Multiple Myeloma )
Date: 2019-09-27 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( Multiple Myeloma )
Date: 2019-07-03 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( Multiple Myeloma )
Date: 2019-05-24 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( Systemic Light Chain Amyloidosis )
Date: 2019-05-24 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( Waldenström's Macroglobulinemia )
Date: 2019-05-24 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2019 ( Multiple Myeloma )
Date: 2018-11-09 Meeting Evidence Panel Disclosures/Attendance
Myelodysplastic Syndromes Panel
Version: 1.2023 ( Myelodysplastic Syndromes )
Date: 2022-08-11 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Myelodysplastic Syndromes )
Date: 2022-06-02 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2022
Date: 2021-11-05 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Myelodysplastic Syndromes )
Date: 2021-04-05 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-08-13 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-04-14 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2020
Date: 2020-02-27 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-04-15 Meeting Evidence Panel Disclosures/Attendance
Myeloproliferative Neoplasms Panel
Version: 3.2023 ( Systemic Mastocytosis )
Date: 2023-06-23 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2023 ( Systemic Mastocytosis )
Date: 2023-05-25 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions )
Date: 2023-04-25 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Myeloproliferative Neoplasms )
Date: 2023-04-25 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Myeloproliferative Neoplasms )
Date: 2022-08-22 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2022 ( Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Fusion Genes )
Date: 2022-10-10 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2022 ( Myeloproliferative Neoplasmsl )
Date: 2022-03-10 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Fusion Genes )
Date: 2021-12-21 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Systemic Mastocytosis )
Date: 2021-12-21 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Myeloproliferative Neoplasms )
Date: 2021-12-07 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2021 ( Systemic Mastocytosis )
Date: 2021-06-24 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2021 ( Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Fusion Genes )
Date: 2020-08-14 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2021 ( Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Fusion Genes )
Date: 2020-07-21 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-08-10 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2020-04-14 Meeting Evidence Panel Disclosures/Attendance
Date: 2020-04-14 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-05-21 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2019
Date: 2019-08-26 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Neuroendocrine and Adrenal Tumors )
Date: 2023-05-25 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Neuroendocrine and Adrenal Tumors )
Date: 2022-10-10 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2022
Date: 2022-12-05 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022
Date: 2022-05-13 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022
Date: 2022-03-28 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-11-19 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-11-08 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-10-25 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2021 ( Neuroendocrine and Adrenal Tumors )
Date: 2021-11-08 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2021-03-26 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2021-01-22 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-12-11 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-11-20 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-11-09 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2020-06-30 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2020-06-01 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-11-18 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2019
Date: 2018-12-13 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2019
Date: 2018-11-01 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2019
Date: 2018-10-29 Meeting Evidence Panel Disclosures/Attendance
Non-Melanoma Skin Cancer Panel
Version: 1.2024 ( Basal Cell Skin Cancer )
Date: 2023-05-01 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Merkel Cell Carcinoma )
Date: 2023-03-24 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Merkel Cell Carcinoma )
Date: 2023-03-10 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Squamous Cell Skin Cancer )
Date: 2023-02-08 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Basal Cell Skin Cancer )
Date: 2023-01-11 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Basal Cell Skin Cancer )
Date: 2022-05-16 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Merkel Cell Carcinoma )
Date: 2022-05-16 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Squamous Cell Skin Cancer )
Date: 2022-05-16 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Basal Cell Skin Cancer and Squamous Cell Skin Cancer )
Date: 2021-10-05 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Merkel Cell Carcinoma )
Date: 2021-05-21 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2021 ( Squamous Cell Skin Cancer )
Date: 2021-08-02 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2021 ( Squamous Cell Skin Cancer )
Date: 2021-07-20 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2021 ( Basal Cell Skin Cancer )
Date: 2021-02-18 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021 ( Squamous Cell Skin Cancer )
Date: 2021-01-14 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021 ( Basal Cell Skin Cancer, Merkel Cell Carcinoma, Squamous Cell Skin Cancer )
Date: 2020-06-18 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2020 ( Squamous Cell Skin Cancer )
Date: 2020-07-01 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( Non-Melanoma Skin Cancers )
Date: 2019-09-10 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( Basal Cell Skin Cancer )
Date: 2019-08-19 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( Merkel Cell Carcinoma )
Date: 2019-08-19 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( Squamous Cell Skin Cancer )
Date: 2019-08-19 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( Basal Cell Skin Cancer )
Date: 2019-06-07 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( Squamous Cell Skin Cancer )
Date: 2019-06-07 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( Merkel Cell Carcinoma )
Date: 2019-05-10 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2019 ( Merkel Cell Carcinoma )
Date: 2018-12-21 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2019 ( Squamous Cell Skin Cancer )
Date: 2018-10-15 Meeting Evidence Panel Disclosures/Attendance
Non-Small Cell Lung Cancer/Mesothelioma/Thymomas and Thymic Carcinomas Panel
Version: 2.2023 ( Non-Small Cell Lung Cancer )
Date: 2023-02-15 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Non-Small Cell Lung Cancer )
Date: 2022-12-12 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Mesothelioma: Peritoneal )
Date: 2022-07-22 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Mesothelioma: Pleural )
Date: 2022-07-22 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Thymomas and Thymic Carcinomas )
Date: 2022-07-22 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Non-Small Cell Lung Cancer )
Date: 2022-07-08 Meeting Evidence Panel Disclosures/Attendance
Version: 6.2022 ( Non-Small Cell Lung Cancer )
Date: 2022-11-18 Meeting Evidence Panel Disclosures/Attendance
Version: 5.2022 ( Non-Small Cell Lung Cancer )
Date: 2022-07-08 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2022 ( Non-Small Cell Lung Cancer )
Date: 2022-08-22 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2022 ( Non-Small Cell Lung Cancer )
Date: 2022-03-09 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Malignant Pleural Mesothelioma )
Date: 2021-07-20 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Thymomas and Thymic Carcinomas )
Date: 2021-07-20 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-07-09 Meeting Evidence Panel Disclosures/Attendance
Version: 7.2021 ( Non-Small Lung Cancer )
Date: 2021-10-15 Meeting Evidence Panel Disclosures/Attendance
Version: 6.2021 ( Non-Small Cell Lung Cancer )
Date: 2021-09-19 Meeting Evidence Panel Disclosures/Attendance
Version: 5.2021 ( Non-Small Cell Lung Cancer )
Date: 2021-06-01 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2021 ( Non-Small Cell Lung Cancer )
Date: 2021-02-23 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2021 ( Non-Small Cell Lung Cancer )
Date: 2021-02-04 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2021 ( Malignant Pleural Mesothelioma )
Date: 2021-02-04 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2021 ( Non-Small Cell Lung Cancer )
Date: 2020-12-08 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021 ( Non-Small Cell Lung Cancer )
Date: 2020-11-09 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021 ( Malignant Pleural Mesothelioma )
Date: 2020-09-04 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021 ( Thymomas and Thymic Carcinomas )
Date: 2020-09-04 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021 ( Non-Small Cell Lung Cancer )
Date: 2020-07-27 Meeting Evidence Panel Disclosures/Attendance
Version: 7.2020 ( Non-Small Cell Lung Cancer )
Date: 2020-09-08 Meeting Evidence Panel Disclosures/Attendance
Version: 6.2020 ( Non-Small Cell Lung Cancer )
Date: 2020-06-03 Meeting Evidence Panel Disclosures/Attendance
Version: 5.2020 ( Non-Small Cell Lung Cancer )
Date: 2020-05-20 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2020 ( Non-Small Cell Lung Cancer )
Date: 2020-05-11 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2020 ( Malignant Pleural Mesothelioma )
Date: 2020-10-09 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2020 ( Non-Small Cell Lung Cancer )
Date: 2019-12-09 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( Malignant Pleural Mesothelioma )
Date: 2019-07-12 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( Non-Small Cell Lung Cancer )
Date: 2019-07-12 Meeting Evidence Panel Disclosures/Attendance
Version: 7.2019 ( Non-Small Cell Lung Cancer )
Date: 2019-08-26 Meeting Evidence Panel Disclosures/Attendance
Version: 6.2019 ( Non-Small Cell Lung Cancer )
Date: 2019-08-04 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2019 ( Non-Small Cell Lung Cancer )
Date: 2019-04-18 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2019 ( Non-Small Cell Lung Cancer )
Date: 2018-11-14 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2019 ( Non-Small Cell Lung Cancer )
Date: 2018-11-14 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2019 ( Malignant Pleural Mesothelioma )
Date: 2018-10-17 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2019 ( Thymomas and Thymic Carcinomas )
Date: 2018-10-17 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2019 ( Non-Small Cell Lung Cancer )
Date: 2018-10-11 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2024 ( Occult Primary )
Date: 2023-04-11 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2023
Date: 2022-10-05 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Occult Primary )
Date: 2022-04-19 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-08-24 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-06-07 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-08-10 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-06-10 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2020
Date: 2020-05-01 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-09-11 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-08-12 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-06-20 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2019
Date: 2018-12-17 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Older Adult Oncology )
Date: 2021-12-03 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-10-22 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2019
Date: 2018-10-11 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2023 ( Ovarian Cancer )
Date: 2023-05-23 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Ovarian Cancer )
Date: 2022-12-08 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Ovarian Cancer )
Date: 2022-12-06 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Ovarian Cancer )
Date: 2022-10-31 Meeting Evidence Panel Disclosures/Attendance
Version: 5.2022 ( Ovarian Cancer )
Date: 2022-09-08 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2022 ( Ovarian Cancer )
Date: 2022-08-16 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2022 ( Ovarian Cancer )
Date: 2022-06-29 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-12-07 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-10-07 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2021
Date: 2021-08-31 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-11-18 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-10-16 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-10-02 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2020-02-10 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-10-23 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2019
Date: 2019-10-23 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2019
Date: 2019-09-12 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2019
Date: 2018-11-28 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2019
Date: 2018-11-15 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023
Date: 2022-07-22 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-08-04 Meeting Evidence Panel Disclosures/Attendance
Pancreatic Adenocarcinoma Panel
Version: 2.2023 ( Pancreatic Adenocarcinoma )
Date: 2023-05-23 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Pancreatic Adenocarcinoma )
Date: 2023-03-16 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Ampullary Adenocarcinoma )
Date: 2023-03-10 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Pancreatic Adenocarcinoma )
Date: 2022-08-12 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2022 ( Ampullary Adenocarcinoma )
Date: 2022-10-14 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2022 ( Pancreatic Adenocarcinoma )
Date: 2022-10-14 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Pancreatic Adenocarcinoma )
Date: 2022-01-24 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Pancreatic Adenocarcinoma )
Date: 2021-08-31 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Pancreatic Adenocarcinoma )
Date: 2021-07-29 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Pancreatic Adenocarcinoma )
Date: 2021-07-08 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-07-23 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-07-09 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-09-16 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-07-30 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-07-16 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2019
Date: 2019-06-17 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2019
Date: 2019-01-31 Meeting Evidence Panel Disclosures/Attendance
Pediatric Acute Lymphoblastic Leukemia Panel
Version: 1.2024
Date: 2023-06-28 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2024
Date: 2023-05-24 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023
Date: 2022-05-25 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-06-09 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2021
Date: 2021-07-13 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-06-12 Meeting Evidence Panel Disclosures/Attendance
Pediatric Aggressive Mature B-Cell Lymphomas Panel
Version: 1.2023
Date: 2022-12-06 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-12-01 Meeting Evidence Panel Disclosures/Attendance
Pediatric Hodgkin Lymphoma Panel
Version: 1.2023
Date: 2022-12-14 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022
Date: 2022-02-08 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-09-10 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2021
Date: 2020-10-16 Meeting Evidence Panel Disclosures/Attendance
Prevention and Treatment of Cancer-Related Infections Panel
Version: 1.2023
Date: 2022-12-05 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-12-08 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-10-20 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-07-31 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-07-26 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-07-10 Meeting Evidence Panel Disclosures/Attendance
Prostate Cancer Early Detection Panel
Version: 1.2023
Date: 2022-12-15 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023
Date: 2022-09-12 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Prostate Cancer Early Detection )
Date: 2021-11-04 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-10-19 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-10-07 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2019
Date: 2018-10-15 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2023
Date: 2023-08-30 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2023
Date: 2023-08-25 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2023
Date: 2023-08-16 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2023
Date: 2023-07-21 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2023 ( Prostate )
Date: 2023-06-12 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Prostate Cancer )
Date: 2022-08-19 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023
Date: 2022-08-09 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023
Date: 2022-07-18 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023
Date: 2022-05-02 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2022
Date: 2022-05-02 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-08-20 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-06-28 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-05-07 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2021
Date: 2021-02-05 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-05-14 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2020
Date: 2020-05-19 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2020
Date: 2020-05-14 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-06-27 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2019
Date: 2019-06-27 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2019
Date: 2019-04-17 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2019
Date: 2019-02-13 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2024
Date: 2023-04-20 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2023 ( Small Cell Lung Cancer )
Date: 2022-04-21 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023
Date: 2022-04-21 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-05-12 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2021
Date: 2021-03-02 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2021
Date: 2021-01-05 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-05-04 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2020
Date: 2020-06-17 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2020
Date: 2019-11-07 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2020
Date: 2019-10-29 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-09-09 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-07-08 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2019
Date: 2018-10-02 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-12-16 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-12-04 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-11-25 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2023 ( Soft Tissue Sarcoma )
Date: 2023-04-12 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Soft Tissue Sarcoma )
Date: 2023-03-09 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Gastrointestinal Stromal Tumors )
Date: 2023-02-03 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Soft Tissue Sarcoma )
Date: 2023-02-03 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Gastrointestinal Stromal Tumors )
Date: 2022-09-13 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Soft Tissue Sarcoma )
Date: 2022-09-13 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Soft Tissue Sarcoma )
Date: 2022-02-16 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Soft Tissue Sarcoma )
Date: 2021-10-19 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Gastrointestinal Stromal Tumors (GISTs) )
Date: 2021-07-09 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Soft Tissue Sarcoma )
Date: 2021-06-11 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2021 ( Soft Tissue Sarcoma )
Date: 2022-01-12 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021 ( Soft Tissue Sarcoma )
Date: 2020-08-25 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021 ( Gastrointestinal Stromal Tumors (GISTs) )
Date: 2020-07-08 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021 ( Soft Tissue Sarcoma )
Date: 2020-07-08 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021 ( Gastrointestinal Stromal Tumors (GISTs) )
Date: 2020-07-07 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021 ( Soft Tissue Sarcoma )
Date: 2020-07-07 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2020
Date: 2020-05-18 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2020-05-05 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-06-19 Meeting Evidence Panel Disclosures/Attendance
Version: 6.2019
Date: 2020-01-31 Meeting Evidence Panel Disclosures/Attendance
Version: 5.2019
Date: 2020-01-14 Meeting Evidence Panel Disclosures/Attendance
Version: 4.2019
Date: 2019-08-28 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2019 ( Soft Tissue Sarcoma )
Date: 2019-08-08 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2019
Date: 2019-01-23 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2019
Date: 2018-12-03 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Survivorship )
Date: 2023-02-02 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Survivorship )
Date: 2021-10-04 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2021
Date: 2021-03-04 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2020-01-31 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2019
Date: 2018-11-30 Meeting Evidence Panel Disclosures/Attendance
T-Cell/Primary Cutaneous Lymphomas Panel
Version: 1.2023 ( T-Cell Lymphomas )
Date: 2022-12-15 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( T-Cell Lymphomas )
Date: 2022-10-31 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Primary Cutaneous Lymphomas )
Date: 2022-10-31 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( Primary Cutaneous Lymphomas )
Date: 2022-07-08 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023 ( T-Cell Lymphomas )
Date: 2022-07-08 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( T-Cell Lymphomas )
Date: 2021-12-17 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( Primary Cutaneous Lymphomas )
Date: 2021-12-03 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022 ( T-Cell Lymphomas )
Date: 2021-07-19 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021 ( Primary Cutaneous Lymphomas )
Date: 2020-07-10 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021 ( T-Cell Lymphomas )
Date: 2020-07-10 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( Primary Cutaneous Lymphomas )
Date: 2019-12-16 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( T-Cell Lymphomas )
Date: 2019-12-16 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( Primary Cutaneous Lymphomas )
Date: 2019-07-19 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020 ( T-Cell Lymphomas )
Date: 2019-07-19 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2019 ( Primary Cutaneous Lymphomas )
Date: 2018-12-11 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2019 ( T-Cell Lymphomas )
Date: 2018-12-11 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2019 ( Primary Cutaneous Lymphomas )
Date: 2018-10-10 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023
Date: 2022-06-17 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-06-18 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-06-19 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2020
Date: 2020-05-06 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2023
Date: 2022-08-15 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2023
Date: 2022-08-15 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2023
Date: 2022-08-15 Meeting Evidence Panel Disclosures/Attendance
Date: 2022-08-15 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2022 ( Thyroid Carcinoma )
Date: 2022-04-22 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2022
Date: 2022-04-22 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2022
Date: 2021-10-27 Meeting Evidence Panel Disclosures/Attendance
Date: 2021-10-27 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2021 ( Thyroid Carcinoma )
Date: 2021-10-15 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2021-04-15 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-10-07 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2021
Date: 2020-10-02 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2020
Date: 2020-12-21 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2020
Date: 2020-06-25 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2020-06-05 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2020-05-26 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-11-22 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2020
Date: 2019-10-07 Meeting Evidence Panel Disclosures/Attendance
Version: 2.2019
Date: 2019-09-04 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2019
Date: 2018-11-05 Meeting Evidence Panel Disclosures/Attendance
Version: 1.2019
Date: 2018-10-29 Meeting Evidence Panel Disclosures/Attendance
Version: 3.2018
Date: 2018-12-03 Meeting Evidence Panel Disclosures/Attendance
No portion of this Site or any NCCN Content may be copied, transferred, reproduced, modified, or otherwise used for any purpose without NCCN’s express written permission.
See Legal Notices Section for additional notices and terms governing your use of this Site.